Compare Lupin Ltd with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs NATCO PHARMA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN NATCO PHARMA LUPIN/
NATCO PHARMA
 
P/E (TTM) x 46.6 15.6 298.2% View Chart
P/BV x 2.4 3.1 77.8% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 LUPIN   NATCO PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-19
NATCO PHARMA
Mar-18
LUPIN/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs9861,080 91.3%   
Low Rs720671 107.3%   
Sales per share (Unadj.) Rs369.5592.1 62.4%  
Earnings per share (Unadj.) Rs13.4188.4 7.1%  
Cash flow per share (Unadj.) Rs37.4206.3 18.1%  
Dividends per share (Unadj.) Rs08.25 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs303.7833.6 36.4%  
Shares outstanding (eoy) m452.4936.90 1,226.3%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.31.5 156.1%   
Avg P/E ratio x63.64.6 1,369.4%  
P/CF ratio (eoy) x22.84.2 537.8%  
Price / Book Value ratio x2.81.1 267.4%  
Dividend payout %04.4 0.0%   
Avg Mkt Cap Rs m386,06432,311 1,194.8%   
No. of employees `00017.74.8 366.1%   
Total wages/salary Rs m31,5133,256 967.8%   
Avg. sales/employee Rs Th9,453.84,522.5 209.0%   
Avg. wages/employee Rs Th1,782.0674.0 264.4%   
Avg. net profit/employee Rs Th343.01,439.0 23.8%   
INCOME DATA
Net Sales Rs m167,18221,848 765.2%  
Other income Rs m3,640404 901.0%   
Total revenues Rs m170,82222,252 767.7%   
Gross profit Rs m28,8229,284 310.5%  
Depreciation Rs m10,850662 1,639.0%   
Interest Rs m3,078154 1,998.9%   
Profit before tax Rs m18,5348,872 208.9%   
Minority Interest Rs m-890-   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,4000-   
Tax Rs m9,0171,920 469.6%   
Profit after tax Rs m6,0666,952 87.2%  
Gross profit margin %17.242.5 40.6%  
Effective tax rate %48.721.6 224.8%   
Net profit margin %3.631.8 11.4%  
BALANCE SHEET DATA
Current assets Rs m138,53621,307 650.2%   
Current liabilities Rs m61,2995,920 1,035.5%   
Net working cap to sales %46.270.4 65.6%  
Current ratio x2.33.6 62.8%  
Inventory Days Days8473 114.4%  
Debtors Days Days112107 105.6%  
Net fixed assets Rs m127,51614,986 850.9%   
Share capital Rs m905369 245.3%   
"Free" reserves Rs m136,51730,353 449.8%   
Net worth Rs m137,42230,760 446.8%   
Long term debt Rs m66,4170-   
Total assets Rs m279,49437,151 752.3%  
Interest coverage x7.058.6 12.0%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.60.6 101.7%   
Return on assets %3.319.1 17.1%  
Return on equity %4.422.6 19.5%  
Return on capital %8.929.3 30.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,41410,322 575.6%   
Fx outflow Rs m22,2822,978 748.1%   
Net fx Rs m37,1327,343 505.7%   
CASH FLOW
From Operations Rs m16,6604,636 359.4%  
From Investments Rs m-32,825-11,155 294.3%  
From Financial Activity Rs m7,4416,509 114.3%  
Net Cashflow Rs m-8,724-18 48,465.0%  

Share Holding

Indian Promoters % 46.6 52.0 89.5%  
Foreign collaborators % 0.2 1.5 13.6%  
Indian inst/Mut Fund % 11.3 7.8 144.1%  
FIIs % 31.9 16.6 191.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 26.0 38.8%  
Shareholders   98,259 25,395 386.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare LUPIN With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; HDFC and TCS Top Gainers(09:30 am)

Asian share markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.1% while the Hang Seng is up 0.9%

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Oct 17, 2019 10:29 AM

TRACK LUPIN

LUPIN - DR. DATSONS LABS COMPARISON

COMPARE LUPIN WITH

MARKET STATS